The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.
about
PMEL: a pigment cell-specific model for functional amyloid formationThe PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB.Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases.Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
P2860
The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@ast
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@en
type
label
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@ast
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@en
prefLabel
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@ast
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@en
P2093
P2860
P356
P1476
The melanosomal protein PMEL17 ...... conjugate therapy in melanoma.
@en
P2093
Cecile Chalouni
Christine Tan
Helga Raab
Paul Polakis
Rachana Ohri
Rayna Venook
Robyn Clark
Ron Firestein
William Mallet
Youjun Chen
P2860
P304
24082-24091
P356
10.1074/JBC.M112.361485
P407
P577
2012-05-21T00:00:00Z